Evidence map›Paper›PMID 33481105›Full record

ArticleActa neuropathologica2021

Supratentorial ependymoma in childhood: more than just RELA or YAP.

Valentina Zschernack, Stephanie T Jünger, Martin Mynarek, Stefan Rutkowski, Maria Luisa Garre, Martin Ebinger, Marie Neu, Jörg Faber, Bernhard Erdlenbruch, Alexander Claviez and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Clinical, surgical, and molecular features of pediatric supratentorial ependymomas: a single-institution experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Article
  4. A brief history of ependymoma.Neuro-oncology · 2026
    Review
  5. Article
  6. NovelCancers · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Sex Differences in Ependymoma Methylation by Methylation-Defined Subgroup.Journal of cellular and molecular medicine · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Ependymoma from Benign to Highly Aggressive Diseases: A Review.Advances and technical standards in neurosurgery · 2024
    Review
  17. Article
  18. Imaging in a new pediatric brain tumor-a supratentorial neuroepithelial tumor with PLAGL1 fusion.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 4 countries.

Valentina Zschernack *Department of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Venusberg-Campus 1, 53127, Bonn, Germany.
Stephanie T Jünger *Department of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Venusberg-Campus 1, 53127, Bonn, Germany.
Martin MynarekDepartment of Pediatric Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Stefan RutkowskiDepartment of Pediatric Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Maria Luisa GarreNeuro-Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Martin EbingerDepartment of Pediatric Hematology and Oncology, University Hospital Tübingen, Tübingen, Germany.
Marie NeuDepartment of Pediatric Hematology/Oncology, Center for Pediatric and Adolescent Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Jörg FaberDepartment of Pediatric Hematology/Oncology, Center for Pediatric and Adolescent Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Bernhard ErdlenbruchJohannes Wesling Klinikum Minden, University Hospital for Children and Adolescents, Ruhr University Hospital, Bochum, Germany.
Alexander ClaviezDepartment of Pediatric and Adolescent Medicine, Pediatric Hematology and Oncology, University Hospital Schleswig Holstein, Kiel, Germany.
Stefan BielackDepartment of Pediatric Oncology, Hematology and Immunology, Center for Pediatric, Adolescent and Women's Medicine, Stuttgart Cancer Center, Klinikum Stuttgart-Olgahospital, Stuttgart, Germany.
Triantafyllia BrozouDepartment of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Michael C FrühwaldUniversity Medical Center Augsburg, Swabian Children's Cancer Center, Augsburg, Germany.
Evelyn DörnerDepartment of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Venusberg-Campus 1, 53127, Bonn, Germany.
Verena DreschmannDepartment of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Venusberg-Campus 1, 53127, Bonn, Germany.
Annika StockDepartment of Neuroradiology, University Hospital Würzburg, Würzburg, Germany.
Laszlo SolymosiDepartment of Neuroradiology, University Hospital Würzburg, Würzburg, Germany.
Jürgen HenchDivision of Neuropathology, Department of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Stephan FrankDivision of Neuropathology, Department of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Christian VokuhlPediatric Pathology, Department of Pathology, University of Bonn Medical Center, Bonn, Germany.
Andreas WahaDepartment of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Venusberg-Campus 1, 53127, Bonn, Germany.
Felipe Andreiuolo *Department of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Venusberg-Campus 1, 53127, Bonn, Germany.
Torsten Pietsch *Department of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Venusberg-Campus 1, 53127, Bonn, Germany. t.pietsch@uni-bonn.de.ORCID 0000-0003-0763-6506
University of Bonn · DEJohannes Gutenberg University Mainz · DEUniversität Hamburg · DEUniversitätsklinikum Würzburg · DEUniversity Hospital of Basel · CHDüsseldorf University Hospital · DEIstituto Giannina Gaslini · ITJohannes Wesling Klinikum Minden · DEOlgahospital · DEUniversity Children's Hospital Tübingen · DEUniversity Hospital Augsburg · DEUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two distinct genetically defined entities of ependymoma arising in the supratentorial compartment are characterized by the presence of either a C11orf95-RELA or a YAP-MAMLD1 fusion, respectively. There is growing evidence that supratentorial ependymomas without these genetic features exist. In this study, we report on 18 pediatric non-RELA/non-YAP supratentorial ependymomas that were systematically characterized by means of their histology, immunophenotype, genetics, and epigenomics. Comprehensive molecular analyses included high-resolution copy number analysis, methylation profiling, analysis of fusion transcripts by Nanostring technology, and RNA sequencing. Based upon histological and immunohistochemical features two main patterns were identified-RELA-like (n = 9) and tanycytic ependymomas (n = 6). In the RELA-like group histologically assigned to WHO grade III and resembling RELA-fused ependymomas, tumors lacked nuclear expression of p65-RelA as a surrogate marker for a pathological activation of the NF-κB pathway. Three tumors showed alternative C11orf95 fusions to MAML2 or NCOA1. A methylation-based brain tumor classifier assigned two RELA-like tumors to the methylation class "EP, RELA-fusion"; the others demonstrated no significant similarity score. Of the tanycytic group, 5/6 tumors were assigned a WHO grade II. No gene fusions were detected. Methylation profiling did not show any association with an established methylation class. We additionally identified two astroblastoma-like tumors that both presented with chromothripsis of chromosome 22 but lacked MN1 breaks according to FISH analysis. They revealed novel fusion events involving genes in chromosome 22. One further tumor with polyploid cytogenetics was interpreted as PFB ependymoma by the brain tumor methylation classifier but had no relation to the posterior fossa. Clinical follow-up was available for 16/18 patients. Patients with tanycytic and astroblastoma-like tumors had no relapse, while 2 patients with RELA-like ependymomas died. Our data indicate that in addition to ependymomas discovered so far, at least two more supratentorial ependymoma types (RELA-like and tanycytic) exist.

Indexed as

Adaptor Proteins, Signal TransducingAdolescentChildChild, PreschoolEpendymomaFemaleHumansInfantMaleSupratentorial NeoplasmsTranscription Factor RelATranscription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingRELA protein, humanTranscription Factor RelATranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsBrain tumorC11orf95 fusionChildhoodEpendymomaMethylation profilingPediatricSupratentorialTanycytic

Identifiers

PMID33481105
PMCPMC7882569
OpenAlexW3124563311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.